Artelo Biosciences, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ARTL | EOCN | CANF | SILO | 18H0.F | EDVA | |
|---|---|---|---|---|---|---|
| Market cap | 1.24M | 2.96M | 5.06M | 2.93M | 5.11M | 2.11M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -2.6 | — | -1.8 | -1.9 | — | — |
| Price/book | 0.2 | 0.2 | 0.7 | 0.3 | -1.1 | 0.0 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −95.42% | −71.44% | −80.71% | −83.17% | −38.46% | −96.76% |
| Today | −5.42% | −1.42% | +3.02% | +3.91% | −23.81% | +3.23% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ARTL news ›Mara Files Second Inter Partes Review (IPR) Petition in the US Challenging Validity of DSM Patent: No.10757959 "Thraustochytrids, fatty acid compositions, and methods of making and uses thereof."
HALIFAX, Canada — Mara Renewables Corporation, and its manufacturing partner Algal Omega-3 (AO3) announced today they have filed a second IPR in the United States challenging DSM Patent No. 10757959 ... HALIFAX, Canada — Mara Renewables…
Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform
Presentation to feature results from first clinical study of ART26.12 and highlight the potential of FABP5 inhibition across multiple indications BIO-Europe provides a key platform to advance ongoing discussions and expand partnering…
Artelo Biosciences to Showcase First-in-Human FABP5 Inhibitor ART26.12 as a Novel Approach to Pain Treatment at IASP 2026 World Congress on Pain
Presentation will introduce ART26.12, the first selective FABP5 inhibitor to enter human clinical studies, to the world’s largest gathering of pai... Artelo Biosciences to Showcase First-in-Human FABP5 Inhibitor ART26.12 as a Novel…
HotSpot Therapeutics to Present Preclinical Data on Small Molecule IRF5 Inhibitor HST-2011 at ACR Convergence 2026
/PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, allosteric small molecules that target... BOSTON, Oct. 28, 2026 /PRNewswire/ -- HotSpot Therapeutics, Inc., a…
Mayne Settles US Patent Suit With Teva Over Generic Imvexxy
Law360 Mayne Settles US Patent Suit With Teva Over Generic Imvexxy By Antony Scholefield · October 16, 2026, 2:39 PM AEST Get instant access to the one-stop news source for business lawyers Email (NOTE: Free email domains not supported)
Artelo Biosciences flagged under Nasdaq $5M MVLS rule; monitoring options to regain compliance
TradingView Artelo Biosciences flagged under Nasdaq $5M MVLS rule; monitoring options to regain compliance Artelo Biosciences disclosed it was identified as below Nasdaq's new $5M MVLS threshold and is ev
Artelo Biosciences initially below $5M Nasdaq threshold
Nasdaq initially identified Artelo among companies below the $5 million market-value threshold; the rule is under a temporary stay, and the filing says the stay’s duration and the rule’s final form remain unknown. Pursuant to Section 13 OR…
Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies
The Patent Claims are for the Intended Commercial Formulation of ART27.13 Expected to Extend Patent Protection for ART27.13 through 2041 SOLANA BEACH, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Artelo ... Artelo Biosciences Receives a…
Artelo Biosciences Presents Evidence for A Common Lipid-Signaling Link Across Multiple Potential Indications for Its Fabp5 Inhibitor Platform At Icrs 2026
Artelo Biosciences announced results utilizing multi-omics analyses that identified a potential mechanistic links across disease models with ART26.12, the Company?s lead selective Fatty Acid Binding... Artelo Biosciences announced results…
Artelo Biosciences Receives Notice Of Allowance For U.S. Patent Covering Intended Commercial Formulation Of ART27.13
Artelo Biosciences, Inc. has received a Notice of Allowance for a U.S. patent application covering the intended commercial formulation of ART27.13, the Company?s peripherally selective cannabinoid... has received a Notice of Allowance for…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com11
- marketscreener.com11
- stocktitan.net2
- financialpost.com1
- prnewswire.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 27 articles, not a forecast.